RA
GSK icon

Rise Advisors’s GSK GSK Stock Holding History

Rise Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9
Closed -$405 – 659
2025
Q3 		$405 Hold
9
– – ﹤0.01% 1446
2025
Q2 		$357 Buy
9
+7
+350% +$267 ﹤0.01% 1461
2025
Q1 		$92 Sell
2
-585
-100% -$21.4K ﹤0.01% 1459
2024
Q4 		$19.8K Buy
587
+6
+1% +$216 0.01% 666
2024
Q3 		$23.8K Buy
581
+5
+0.9% +$205 0.01% 567
2024
Q2 		$22.2K Buy
576
+6
+1% +$252 0.01% 567
2024
Q1 		$24.4K Buy
+570
New +$23.5K 0.01% 508
2023
Q2 		– Sell
-41
Closed -$1.45K – 724
2023
Q1 		$1.45K Buy
41
+1
+3% +$35 ﹤0.01% 609
2022
Q4 		$1.42K Hold
40
– – ﹤0.01% 612
2022
Q3 		$1K Sell
40
-1
-2% -$38 ﹤0.01% 629
2022
Q2 		$2K Buy
41
+1
+3% +$55 ﹤0.01% 553
2022
Q1 		$2K Buy
+40
New +$2.17K ﹤0.01% 532

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rise Advisors's GSK Position: Q4 2025 in Review

Rise Advisors sold out of GSK (GSK) in Q4 2025, closing a stake of 9 shares — an estimated $405 sold.

Rise Advisors first reported a position in GSK in Q1 2022 and held it in 12 quarters. The position peaked at $24.4K in Q1 2024. 998 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

  • Rise Advisors reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 9 GSK shares in Q4 2025, an estimated $405.
  • Rise Advisors first reported a position in GSK in Q1 2022 and held it in 12 quarters.
  • Rise Advisors's GSK position peaked at $24.4K in Q1 2024.
  • 998 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.